Literature DB >> 8900156

Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.

J L Greene1, G M Leytze, J Emswiler, R Peach, J Bajorath, W Cosand, P S Linsley.   

Abstract

T lymphocyte receptors CD28 and CTLA-4 bind costimulatory molecules CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells and regulate T cell activation. While distinct functional roles have been ascribed to each of these molecules, little is known about how they interact. To better characterize these interactions, we have used surface plasmon resonance to perform equilibrium and kinetic binding analyses of extracellular fragments of CD28/CTLA-4/CD80/CD86. We show that CTLA-4 and CD28 binding are both characterized by rapid kinetic on-rates and rapid dissociation rates. Native disulfide-linked homodimers of CD28 and CTLA-4 bound with two kinetically distinct binding sites, one of high avidity and slow dissociation and one of low avidity and more rapid dissociation. Monomeric CTLA-4 bound only with low affinity and rapid dissociation. Therefore, covalent dimerization of CTLA-4 is required for its high avidity binding. Oligomerization of CD80/CD86 is also required for high avidity CTLA-4 binding since CTLA-4 bound with low avidity to monomeric CD86. This contrasts with the ability of CD80/CD86 on antigen-presenting cells to bind CTLA4Ig with high avidity and predicts their organization as oligomers or clusters that permit multivalent binding. Thus, covalent receptor dimerization and ligand oligomerization are two key features of the CD28/CTLA-4/CD80/CD86 receptor system that control ligand binding and may regulate signal transduction by controlling the duration of receptor occupancy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900156     DOI: 10.1074/jbc.271.43.26762

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge.

Authors:  G Deliyannis; J S Boyle; J L Brady; L E Brown; A M Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Crystal structure of the receptor-binding domain of human B7-2: insights into organization and signaling.

Authors:  Xuewu Zhang; Jean-Claude D Schwartz; Steven C Almo; Stanley G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-26       Impact factor: 11.205

3.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Authors:  J R Abrams; M G Lebwohl; C A Guzzo; B V Jegasothy; M T Goldfarb; B S Goffe; A Menter; N J Lowe; G Krueger; M J Brown; R S Weiner; M J Birkhofer; G L Warner; K K Berry; P S Linsley; J G Krueger; H D Ochs; S L Kelley; S Kang
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

4.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 5.  Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.

Authors:  Alison M Gizinski; David A Fox; Sujata Sarkar
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-08       Impact factor: 4.098

6.  The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function.

Authors:  Eszter Lazar-Molnar; Steven C Almo; Stanley G Nathenson
Journal:  Cell Immunol       Date:  2007-04-30       Impact factor: 4.868

Review 7.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

8.  Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis.

Authors:  Amy Dhirapong; Guo-Xiang Yang; Steven Nadler; Weici Zhang; Koichi Tsuneyama; Patrick Leung; Stuart Knechtle; Aftab A Ansari; Ross L Coppel; Fu-Tong Liu; Xiao-Song He; M Eric Gershwin
Journal:  Hepatology       Date:  2013-02       Impact factor: 17.425

Review 9.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

Review 10.  ANCA-associated vasculitis: from bench research to novel treatments.

Authors:  Lalit Pallan; Caroline O Savage; Lorraine Harper
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.